HM15275

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Type 2 Diabetes MellitusDiabetes Mellitus

150 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

1

Maridebart Cafraglutide

Amgen

Phase 3

32

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

13

GZR18

GGan & Lee Pharmaceuticals.

Phase 3

54

HDM1002

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3

35

GZR4

GGan and Lee Pharmaceuticals, USA

Phase 3

56

HM11260C

Hanmi Pharmaceutical Company Limited

Phase 3

37

TG103

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase 3

28

Adenocard

Astellas

Preclinical

19

NOVOLIN R

Novo Nordisk

Preclinical

110

Myrbetriq

Astellas

Preclinical

—Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Phase 11 trial

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

Completed·Hanmi Pharmaceutical Company Limited·Phase 1·NCT06481098·74 enrolled

Diabetes Mellitus1 trial

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

Recruiting·Hanmi Pharmaceutical Company Limited·Phase 2·NCT07205900·250 enrolled

Type 2 Diabetes Mellitus1 trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Subjects With Type 2 Diabetes Mellitus

Recruiting·Hanmi Pharmaceutical Company Limited·Phase 2·NCT07527650·180 enrolled

Details

Drug Info

Related News